 |
|
|
| |
Resistance Profile of HIV-1 Maturation Inhibitor GSK3532795 / GSK28338232
|
| |
| |
Pharm Wk: Early Safety, Tolerability and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects - (06/20/17)
HIV Combinectin GSK3732394: A Long-Acting Inhibitor With Multiple Modes of Action - (10/30/16)
HIV-1 Attachment Inhibitor Prodrug BMS-663068 [GSK3684934 (formerly BMS-663068)] in Antiretroviral-Experienced Subjects: Week 96 Safety Analysis - (11/02/16)
HIV-1 Attachment Inhibitor Prodrug BMS-663068 [GSK3684934 (formerly BMS-663068)] in Antiretroviral-Experienced Subjects: Week 96 Subgroup Analysis - (10/30/16)
The Effect of Food on the Pharmacokinetics of the HIV-1 Attachment Inhibitor Temsavir, the Active Moiety of the Prodrug Fostemsavir - (06/26/17)
The Effect of Increased Gastric pH on the Bioavailability of Extended Release Tablet of Fostemsavir in Healthy Subjects / Combinectin-GSK3732394 / 2nd Gen Maturation Inhibitor GSK2838232 - (06/26/17)
Reported by Jules Levin
9th IAS Conference on HIV Science; July 23-26, 2017; Paris, France
Ira Dicker,1 Beata Nowicka-Sans,1*Sharon Zhang,1Neelanjana Ray,3Brett Beno,3Alicia Regueiro-Ren,3Samit Joshi,2Mark Cockett,1Mark Krystal,1and Max Lataillade2
ViiV Healthcare, Departments of 1Discovery and 2Development, Wallingford, CT 06492, USA; 3Bristol-Myers Squibb, Research and Development, Wallingford, CT 06492 and Princeton, NJ 08648, USA
*Deceased.
|
| |
|
|
|
|
|
